Literature DB >> 19175546

Very high users of platelet transfusions in the neonatal intensive care unit.

M Lynn Dohner1, Susan E Wiedmeier, Ronald A Stoddard, Donald Null, Diane K Lambert, Jill Burnett, Vickie L Baer, Joshua C Hunt, Erick Henry, Robert D Christensen.   

Abstract

BACKGROUND: In neonatal intensive care unit (NICU) practice, a small percentage of the patients receive a large proportion of the platelet (PLT) transfusions administered. This study sought to better define this very-high-user group. To accomplish this, records of all NICU patients in a multihospital health care system who, during a recent 5(1/2)-year period, received 20 or more PLT transfusions were examined. STUDY DESIGN AND METHODS: Electronic medical record repositories of Intermountain Healthcare neonates with dates of birth from January 1, 2002, through June 30, 2007, who received 20 or more PLT transfusions were identified. The causes of the thrombocytopenia were sought, whether each transfusion given was a treatment for bleeding versus prophylaxis was determined, whether each transfusion was compliant with our transfusion guidelines was judged, and the outcomes were tabulated.
RESULTS: During this period, 45 patients received 20 or more PLT transfusions (median, 29; range, 20-79). Medical conditions could be categorized into six diagnoses: 1) extracorporeal membrane oxygenation (ECMO) for congenital diaphragmatic hernia (CDH; n = 13), 2) fungal sepsis (n = 8), 3) ECMO for reasons other than CDH (n = 8), 4) necrotizing enterocolitis (n = 7), 5) bacterial sepsis (n = 7), and 6) congenital hyporegenerative thrombocytopenia (n = 2). Nineteen percent of the transfusions were ordered for oozing, bruising, or bleeding and 81 percent for prophylaxis. Thirty-six percent of transfusions were given in violation of our transfusion guidelines. Forty-nine percent of the high users died, but no deaths were due to hemorrhage. All survivors developed chronic lung disease, and all survivors weighing less than 1250 g at birth developed retinopathy of prematurity.
CONCLUSIONS: Almost all patients that received 20 or more PLT transfusions had an acquired, consumptive thrombocytopenia. All could have received fewer transfusions had the guidelines already in place been observed. Eighty-one percent fewer PLT transfusions would have been administered had the paradigm been transfusing only if oozing, bruising, or bleeding was present.

Entities:  

Mesh:

Year:  2009        PMID: 19175546     DOI: 10.1111/j.1537-2995.2008.02074.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  10 in total

Review 1.  Neonatal thrombocytopenia and megakaryocytopoiesis.

Authors:  Francisca Ferrer-Marin; Zhi-Jian Liu; Ravi Gutti; Martha Sola-Visner
Journal:  Semin Hematol       Date:  2010-07       Impact factor: 3.851

2.  Eltrombopag, a thrombopoietin mimetic, crosses the blood-brain barrier and impairs iron-dependent hippocampal neuron dendrite development.

Authors:  T W Bastian; K A Duck; G C Michalopoulos; M J Chen; Z-J Liu; J R Connor; L M Lanier; M C Sola-Visner; M K Georgieff
Journal:  J Thromb Haemost       Date:  2017-02-16       Impact factor: 5.824

3.  Pediatric Plasma and Platelet Transfusions on Extracorporeal Membrane Oxygenation: A Subgroup Analysis of Two Large International Point-Prevalence Studies and the Role of Local Guidelines.

Authors:  Marianne E Nellis; Arun Saini; Philip C Spinella; Peter J Davis; Marie E Steiner; Marisa Tucci; Melissa Cushing; Pierre Demaret; Simon J Stanworth; Stephane Leteurtre; Oliver Karam
Journal:  Pediatr Crit Care Med       Date:  2020-03       Impact factor: 3.624

4.  Developmental differences between newborn and adult mice in response to romiplostim.

Authors:  Katherine A Sparger; Haley Ramsey; Viola Lorenz; Zhi-Jian Liu; Henry A Feldman; Nan Li; Tahirih Laforest; Martha C Sola-Visner
Journal:  Platelets       Date:  2017-05-26       Impact factor: 3.862

5.  Effects of in vitro adult platelet transfusions on neonatal hemostasis.

Authors:  F Ferrer-Marin; C Chavda; M Lampa; A D Michelson; A L Frelinger; M Sola-Visner
Journal:  J Thromb Haemost       Date:  2011-05       Impact factor: 5.824

Review 6.  Neonatal platelet physiology and implications for transfusion.

Authors:  Francisca Ferrer-Marín; Martha Sola-Visner
Journal:  Platelets       Date:  2021-08-16       Impact factor: 3.862

7.  Plasma and Platelet Transfusions Strategies in Neonates and Children Undergoing Cardiac Surgery With Cardiopulmonary Bypass or Neonates and Children Supported by Extracorporeal Membrane Oxygenation: From the Transfusion and Anemia EXpertise Initiative-Control/Avoidance of Bleeding.

Authors:  Jill M Cholette; Jennifer A Muszynski; Juan C Ibla; Sitaram Emani; Marie E Steiner; Adam M Vogel; Robert I Parker; Marianne E Nellis; Melania M Bembea
Journal:  Pediatr Crit Care Med       Date:  2022-01-01       Impact factor: 3.971

Review 8.  Neonatal platelets: mediators of primary hemostasis in the developing hemostatic system.

Authors:  Kristina M Haley; Michael Recht; Owen J T McCarty
Journal:  Pediatr Res       Date:  2014-06-18       Impact factor: 3.756

Review 9.  Transfusion in Neonatal Patients: Review of Evidence-Based Guidelines.

Authors:  Patricia E Zerra; Cassandra D Josephson
Journal:  Clin Lab Med       Date:  2020-12-23       Impact factor: 2.172

10.  Risk factors for severity of thrombocytopenia in full term infants: a single center study.

Authors:  Amira M Saber; Shereen P Aziz; Al Zahraa E Almasry; Ramadan A Mahmoud
Journal:  Ital J Pediatr       Date:  2021-01-12       Impact factor: 2.638

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.